SUPPLEMENTARY MATERIAL

Alcohol abuse/dependence

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		9.21 (.002)	32.63 (<.001)	12.00 (<.001)	2.68 (.101)
		\mathbf{AN}^*	BN	ANBN	
AN			12.18 (<.001)	5.30 (.021)	.49 (.486)
			BN	ANBN	
BN				.01 (.940)	1.48 (.223)
ANBN					1.08 (.299)
BED					

^{*} Bolded group represents higher prevalence.

Diet pills-weekly

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		35.63 (<.001)	66.46 (<.001)	47.96 (<.001)	1.30 (.255)
		AN*	BN	ANBN	BED
AN			16.15 (<.001)	33.44 (<.001)	1.94 (.163)
			BN	ANBN	
BN				12.46 (<.001)	12.55 (<.001)
				ANBN	BN
ANBN					27.88 (<.001)
					ANBN
BED					

Note. no ED = no eating disorder, AN = anorexia nervosa, BN = bulimia nervosa,

ANBN = lifetime history of AN and BN, BED = binge eating disorder.

^{*} Bolded group represents higher prevalence.

Cannabis 10x/month

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		11.71 (<.001)	5.46 (.019)	2.82 (.093)	3.22 (.073)
		AN*	BN		
AN			.26 (.613)	.00 (.980)	.75 (.388)
			, ,	, ,	, , ,
BN				.09 (.758)	1.09 (.296)
				, ,	
ANBN					.63 (.427)
					` ,
BED					

^{*} Bolded group represents higher prevalence.

Cannabis-ever

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		13.51 (<.001)	25.20 (<.001)	4.74 (.030)	6.63 (.010)
		AN*	BN	ANBN	BED
AN			3.50 (.061)	.17 (.680)	2.09 (.148)
			, ,	, ,	
BN				.77 (.381)	.25 (.620)
				, ,	` ,
ANBN					.98 (.322)
					` ′
BED					

^{*} Bolded group represents higher prevalence.

Hallucinogens-ever

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		5.66 (.017)	2.52 (.113)	2.49 (.115)	.32 (.572)
		AN*	, ,	,	` ,
AN			.11 (.735)	.32 (.572)	.23 (.631)
					` ,
BN				.56 (.456)	.40 (.526)
ANBN					.00 (.997)
BED					

^{*} Bolded group represents higher prevalence.

Opioids 10x/month

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		5.77 (.016)	3.07 (.080)	3.22 (.073)	.02 (.895)
		AN*			
AN			.08 (.781)	.54 (.462)	1.0 (.318)
			, ,	, , , ,	, , ,
BN				.78 (.379)	.62 (.433)
				, , , ,	
ANBN					1.71 (.191)
BED					

^{*} Bolded group represents higher prevalence.

Opioids-ever

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		10.98 (<.001)	4.72 (.030)	.47 (.492)	1.15 (.284)
		AN*	BN	, ,	, ,
AN			.34 (.561)	1.10 (.294)	.05 (.829)
BN				.37 (.545)	.01 (.917)
ANBN					.24 (.622)
BED					

^{*} Bolded group represents higher prevalence.

Sedatives 10x/month

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		6.51 (.011)	5.37 (.021)	3.09 (.079)	.56 (.453)
		AN*	BN		
AN			.05 (.832)	.48 (.486)	.06 (.813)
			, ,		, ,
BN				.30 (.582)	.12 (.730)
ANBN					.49(.486)
					, , ,
BED					

^{*} Bolded group represents higher prevalence.

Sedatives-ever

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		20.64 (<.001)	16.06 (<.001)	5.23 (.022)	5.12 (.024)
		AN*	BN	ANBN	BED
AN			.06 (.801)	.00 (.953)	.69 (.407)
BN				.01 (.912)	.47 (.491)
ANBN					.47 (.492)
BED					

^{*} Bolded group represents higher prevalence.

Stimulants 10x/month

	No ED	AN χ^2 (p-value)	BN χ^2 (p-value)	ANBN χ^2 (p-value)	$\begin{array}{c} \text{BED}^{\dagger} \\ \chi^2 \text{ (p-value)} \end{array}$
No ED		6.93 (.009) AN *	.67 (.413)	2.46 (.117)	
AN			2.92 (.088)	.17 (.677)	
BN				1.65 (.199)	
ANBN					
BED					

^{*} Bolded group represents higher prevalence.

[†]BED was removed from GEE analyses due to zero cell sizes.

Stimulants-ever

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		12.59 (<.001)	12.51 (<.001)	2.72 (.099)	.51 (.474)
		AN*	BN		
AN			.45 (.504)	.01 (.936)	.71 (.399)
			, , ,	, , ,	, , ,
BN				.27 (.601)	1.50 (.221)
				, , ,	, , ,
ANBN					.37 (.542)
					` '
BED					

^{*} Bolded group represents higher prevalence.

Polysubstance 10x/month*

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		8.62 (.003)	2.75 (.097)	2.76 (.097)	.43 (.514)
		AN*	, ,	, ,	` ,
AN			.94 (.332)	.11 (.741)	.39 (.534)
			, ,	, ,	` ,
BN				.77 (.381)	.01 (.942)
ANBN					.52 (.472)
BED					

^{*} Bolded group represents higher prevalence.

Polysubstance-ever

	No ED	AN	BN	ANBN	BED
		χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)	χ^2 (p-value)
No ED		21.04 (<.001)	21.69 (<.001)	6.08 (.014)	2.73 (.099)
		$\mathbf{A}\mathbf{N}$	BN*	ANBN	
AN			.77 (.381)	.07 (.792)	.01 (.933)
BN				.11 (.745)	.32 (.572)
ANBN					.06 (.802)
BED					

^{*} Bolded group represents higher prevalence.